Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High pre-treatment neutrophil-to-lymphocyte ratio as a prognostic marker for worse survival in patients with recurrent/metastatic cervical cancer treated with immune checkpoint inhibitors.
Calo CA, Barrington DA, Brown M, Gonzalez L, Baek J, Huffman A, Benedict J, Backes F, Chambers L, Cohn D, Copeland L, Cosgrove C, Nagel C, O'Malley D, Bixel K. Calo CA, et al. Gynecol Oncol Rep. 2022 Jul 8;42:101040. doi: 10.1016/j.gore.2022.101040. eCollection 2022 Aug. Gynecol Oncol Rep. 2022. PMID: 35855965 Free PMC article.
Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes.
Levine MD, Barrington DA, Meade CE, Lammers SM, McLaughlin EM, Suarez AA, Backes FJ, Copeland LJ, O'Malley DM, Cosgrove CM, Cohn DE, Nagel CI, Felix AS, Bixel KL. Levine MD, et al. Among authors: nagel ci. Gynecol Oncol. 2023 Jun;173:15-21. doi: 10.1016/j.ygyno.2023.03.023. Epub 2023 Apr 8. Gynecol Oncol. 2023. PMID: 37037083
Prevalence of type 2 diabetes diagnoses in the perioperative and survivorship periods following surgical management of endometrial cancer: An opportunity for screening and intervention?
Morton M, McLaughlin EM, Calo CA, Lightfoot M, Bixel KL, Cohn DE, Cosgrove CM, Copeland LJ, O'Malley DM, Nagel CI, Chambers LM. Morton M, et al. Among authors: nagel ci. Gynecol Oncol. 2023 Oct;177:46-52. doi: 10.1016/j.ygyno.2023.08.009. Epub 2023 Aug 26. Gynecol Oncol. 2023. PMID: 37639902
The impact of antibiotic and proton pump inhibitor use at the time of adjuvant platinum-based chemotherapy on survival in patients with endometrial cancer.
Haight PJ, Kistenfeger Q, Riedinger CJ, Khadraoui W, Backes FJ, Bixel KL, Copeland LJ, Cohn DE, Cosgrove CM, O'Malley DM, Nagel CI, Spakowicz DJ, Chambers LM. Haight PJ, et al. Among authors: nagel ci. Gynecol Oncol. 2023 Nov;178:14-22. doi: 10.1016/j.ygyno.2023.09.005. Epub 2023 Sep 21. Gynecol Oncol. 2023. PMID: 37741201
Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
Levine MD, Wang H, Sriram B, Khan A, Senter L, McLaughlin EM, Bixel KL, Chambers LM, Cohn DE, Copeland LJ, Cosgrove CM, Nagel CI, O'Malley DM, Backes FJ. Levine MD, et al. Among authors: nagel ci. Gynecol Oncol. 2024 Mar;182:51-56. doi: 10.1016/j.ygyno.2023.12.008. Epub 2024 Jan 22. Gynecol Oncol. 2024. PMID: 38262238
39 results